E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Resectable soft tissue sarcomas |
|
E.1.1.1 | Medical condition in easily understood language |
a sarcoma that qualifies for surgical treatment |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10029104 |
E.1.2 | Term | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluation of the efficacy of pembrolizumab and eftilagimod alfa in combination with preoperative radiotherapy in patients with resectable soft tissue sarcomas by analyzing the pathological response in the postoperative material. |
|
E.2.2 | Secondary objectives of the trial |
Secondary Objectives: • assessment of the pathological response according to EORTC-STBSG criteria • assessment of radiological response according to RECIST 1.1 criteria • assessment of disease-free survival (DFS), local relapse-free survival (LRFS) and distant metastasis free survival (DMFS) and overall survival (OS) • evaluation of the safety of the combination of pembrolizumab with eftilagimod alfa • assessment of patients' quality of life (EORTC QLQ-C30 scale and FACT- G) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-Willing and able to provide written informed consent for the trial. -Be ≥ 18 years of age on day of signing informed consent. -Performance status of 0 to 1 on the ECOG Performance Scale. -Primary or locally recurrent deep-seated extremities, girdles and/or superficial trunk (thoracic or abdominal wall) soft tissue sarcoma -Grade 2 or 3 tumors according FNCLCC. -Size of the primary tumor >5 cm at instrumental staging (CT, MRI), or locally recurrent of any size; - Measurable disease based on RECIST 1.1; -Non-metastatic disease. -No previous systemic treatment for sarcoma. |
|
E.4 | Principal exclusion criteria |
- Ewing sarcoma, Alveolar and embryonal rhabdomyoarcoma. -Previous treatment with eftilagimod alpha, anty-PD-1 or ant-PD-L1. -Prior radiotherapy to tumor-involved sites. -Subjects with active, known or suspected autoimmune disease or inflammatory bowel disease, which, in the opinion of the investigator, might impair the subject’s tolerance of trial treatment. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring replacement therapy, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. -A concomitant disease that, in the opinion of the investigator, poses an unacceptable risk to the patient if he or she participates in the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of the study is the pathological response, defined as percentage of fibrosis and hyalinization found in the surgical specimen after completion of preoperative treatment. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Histopathological examination of the excised tumor - resection in the 11th - 12th week of the study. |
|
E.5.2 | Secondary end point(s) |
-Treatment safety profile. -Number of patients completing neoadjuvant treatment and having a curative surgery according to the protocol. -Disease-free survival time (DFS) - Local recurrence-free survival (LRFS) - Distant metastasis-free survival (DMFS) - Overall survival (OS) -Overall response rate (ORR) by RECIST 1.1 criteria. -Exploratory endpoints include the search for biomarkers and correlations between their occurrence and response to treatment. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Adverse reactions - on every visit. Survival based on imaging studies performed every 12 weeks. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |